Abstract 5091: Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin's lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-5091
Abstract: Aggressive non-Hodgkin9s lymphoma (NHL) progresses rapidly. It makes up about 60% of all NHL cases in the United States. The chemotherapy regimen R-CHOP could cure up to 70% of patients with aggressive NHL. Nonetheless, up… read more here.
Keywords: lymphoma; aggressive nhl; group; mice treated ... See more keywords
Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1750
Abstract: INTRODUCTION Rituximab mediated antibody-dependent cellular cytotoxicity (ADCC) is an essential component of therapy in B-cell malignancies. The efficiency of cellular cytotoxicity depends on many factors including rituximab binding, lytic granule release and perforin/granzyme concentration, or… read more here.
Keywords: chop; patients aggressive; aggressive nhl; trial ... See more keywords
Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5523
Abstract: Introduction Aggressive B-NHL includes rare subtypes such as transformed diffuse large B-cell lymphoma (t-DLBCL), high-grade B-cell lymphoma not otherwise specified (HGBL NOS), primary mediastinal B-cell lymphoma (PMBL), and follicular lymphoma (FL) Grade (Gr) 3b, for… read more here.
Keywords: treatment; rate; aggressive nhl; efficacy ... See more keywords
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008240
Abstract: Most patients receiving CAR T-cell therapy (CAR-T) for aggressive B-cell lymphoma (B-NHL) will not experience a durable remission. There are several novel agents approved for the treatment relapsed, refractory aggressive B-NHL; however, it remains unclear… read more here.
Keywords: car; car failure; aggressive nhl; post car ... See more keywords
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Cancer"
DOI: 10.1186/s12943-024-02123-7
Abstract: Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity… read more here.
Keywords: aggressive nhl; nhl dlbcl; cd16; dlbcl patients ... See more keywords